Anticoagulation with Intravenous Direct Thrombin Inhibitors in Pediatric Extracorporeal Membrane Oxygenation: A Systematic Review of the Literature

Abstract

Although intravenous (IV) direct thrombin inhibitors (DTI) have gained interest in pediatric extracorporeal membrane oxygenation (ECMO), dosing and safety information is limited. The objective of this systematic review was to characterize DTI types, dosing, monitoring, and outcomes (bleeding and thromboembolic) in pediatric ECMO patients managed with IV DTIs. We conducted searches of MEDLINE (Ovid) and Embase (Elsevier) from inception through December 2022. Case reports, retrospective studies, and prospective studies providing per-patients or summary data for patient(s) <18 years of age receiving IV DTI for ECMO anticoagulation were included. Study selection and data extraction were conducted independently by two reviewers. A total of 28 studies: 14 case reports, 13 retrospective studies, and 1 prospective study were included, totaling 329 patients. Bivalirudin was utilized in 318 (96.7%), argatroban in 9 (2.7%), and lepirudin in 2 (0.6%) patients. Infusion dosing included: bivalirudin 0.14 ± 0.37 mg/kg/h, argatroban 0.69 ± 0.73 µg/kg/min, lepirudin 0.14 ± 0.02 mg/kg/h. Laboratory monitoring tests utilized were the activated clotting time, activated partial thromboplastin time (aPTT), diluted thrombin time, and thromboelastography measures. The aPTT was utilized in most patients (95%). Thromboembolism, bleeding, or death were observed in 17%, 17%, and 23% of bivalirudin, argatroban, and lepirudin patients, respectively. Bivalirudin appears to be the most frequently used DTI in pediatric ECMO. Dosing and laboratory monitoring varied, and bleeding and thromboembolic events were reported in 17% of patients. Prospective studies are warranted to establish dosing, monitoring, safety, and efficacy of bivalirudin and other IV DTI in pediatric ECMO.

2023 Eberhard F. Mammen Award Announcements: Part II–Young Investigator Awards

“…Amy has already previously published in STH, with a total of six papers, the most recent two as first author. 3 4 She is currently working in the Divisions of Pediatric Hematology and Cardiology, Department of Pediatrics, at the Johns Hopkins School of Medicine, and in the Department of Pharmacy at Johns Hopkins All Children's Hospital in the United States. She received her pharmacy degree from the University of Florida and completed pediatric pharmacy residency at the Texas Children's Hospital.…”

Recent Advances in Thrombosis and Hemostasis—Part IX

“…For the pediatric population, there are minimal data regarding use and dosing of direct thrombin inhibitors for ECMO, but Kiskaddon and colleagues have here performed a systematic review of the literature and they identified one prospective and 13 retrospective studies as well as several case reports. 12 Bivalirudin seems to be the most commonly reported (and probably used) direct thrombin inhibitor, but there was substantial variability in the dose regimens and the type of monitoring test used.…”